Home 2018-11-08T12:18:26+00:00

Giving Hope.

From the minute you walk through our door,
our focus is on you.

OFFICE HOURS

Mon – Thurs 8:00am – 4:30pm
Friday 8:00am – 12:00pm

704.947.6599

Welcome to
Carolina BioOncology Institute

At Carolina BioOncology Institute we care for the person, and the disease.

OUR HEALTH SERVICES

OUR FOUNDER

John Powderly, MD  CPI

President  |  CEO

Dr. John Powderly attended Georgetown Medical School from 1991-95 and was awarded the Lawrence Dean Scholarship. His 4th year of Med School was spent at National Cancer Institute (NCI) as an internship on the Immunotherapy Service.   From 1995-1999 he attended the University of Texas, at Houston Health Science Center for a combined Medicine/Pediatrics Residency. In 1999-2000 he was appointed faculty at MD Anderson Cancer Center and performed additional immunotherapy research.  His oncology fellowship at University of North Carolina, Chapel Hill from 2000-02 focused on dendritic cell immunotherapy.

OUR TEAM

Carolina BioOncology Institute has gathered a word class team of medical professionals dedicated to furthering the health and welfare of each patient that comes through our doors. For a detailed view of each team member please click the button below.

MEET OUR TEAM

TOUR OUR FACILITIES

You’re invited to come by and get a complete tour of our facilities.

CLINICAL TRIALS

Clinical trial participants have the opportunity to receive new research treatments before they are widely available. With Phase 1 clinical trial units at our headquarters in Huntersville, NC, we’re able to enroll patients in the newest, most promising trials, without the need for long-distance travel.

Protocol INCAGN 2385-101

Wave

A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies
Sponsor:
InCyte Biosciences Internationals Sarl
Status:
Active, enrolling

Protocol M16-312

Wave

An Open Label, Phase 1 Study of SC-006 as a Single Agent and in Combination with ABBV-181 in Subjects with Advanced Colorectal Cancer
Sponsor:
AbbVie
Status:
Upcoming

Protocol MGD007-02

Wave

A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 DART® Protein in Combination with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Metastatic Colorectal Carcinoma
Sponsor:
MacroGenics
Status:
Upcoming

Protocol CPI-006-001

Wave

A Phase 1/1b multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with Pembrolizumab in adult subjects with advanced cancers.
Sponsor:
Corvus Pharmaceuticals
Status:
Active, enrolling
https://www.clinicaltrials.gov/ct2/show/NCT03454451

Protocol INCAGN 1949-201

Wave

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies.
Sponsor:
Incyte
Status:
Enrolling
https://www.clinicaltrials.gov/ct2/show/NCT03241173

Protocol TAB001-01

Wave

A Phase I, Multicenter; Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects with Advanced Malignancies
Sponsor:
Top Alliance Biosciences, Inc.
Status:
Upcoming